Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”, “SLP”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced that Shawn O’Connor, Chief Executive Officer, will be participating in the upcoming investor conferences...
10 Most Read Journal Articles of 2025
In drug development, the science never stands still. Constant research means there is constantly more to know and understand to stay current—but how can you filter through to what is most impactful?
Design, Synthesis, and Pharmacological Evaluation of Metabolically Stable Apelin Receptor Antagonists with Improved In Vivo Exposure and Efficacy in Ovarian Cancer
The apelin receptor (APJ) has emerged as a potential novel therapeutic target in cancer due to its role in regulating cell proliferation, angiogenesis, and metastasis.
Novel Descriptors and Models for More Accurate ADME Predictions of Beyond Rule of Five Molecules
This study addresses the critical need for improved physicochemical descriptors and predictive models tailored to beyond Rule of Five (bRo5) compounds, including PROTACs and cyclic peptides. B
Clinical Pharmacology Considerations and Modeling of CAR-T Cell Therapies Using Monolix®
Chimeric antigen receptor T-cell (CAR-T) therapies have revolutionized the treatment of hematologic malignancies, delivering durable responses in patients with relapsed and refractory cancers.
Simulations Plus Highlights Platform Innovation and Strategic Direction at 2026 Investor Day
Showcases platform momentum, strategic priorities, and long-term value creation outlook
Unveiling Anticancer Potential of Imidazo-Pyridine/Pyrazine-Fused bicyclic Heterocycles: Insights From in silico and in vitro Studies
Cancer is a significant global health challenge and the second leading cause of death worldwide, responsible for millions of fatalities annually.
Supramolecular Organogels Based on Cinnarizine as a Potential Gastroretentive System: In Vitro and In Silico Simulations
Gastroretentive systems are an interesting option for enhancing the bioavailability of weak bases and poorly soluble drugs.
Simulations Plus Reports First Quarter Fiscal 2026 Financial Results
Investor Day on January 21, 2026, to present new product vision and AI solutions
How to Streamline Your DMTA Cycle While Being ADMET Aware From the First Iteration
Drug discovery has always been a balancing act, with scientists constantly striving for ‘Goldilocks’ compounds – the search for molecules that achieve on-target activity, while also avoiding hidden liabilities such as toxicity, poor exposure, or unfavorable pharmacokinetics, can seem insurmountable at times.
Exploration of IVIVC Deconvolution Methods in a PBPK Platform: Case Example with Tofacitinib
Modified-release (MR) drug products are designed to provide controlled drug delivery over time, offering therapeutic and compliance advantages.
Oral Pro‑Transferosome Tablets of Carica papaya Leaf Extract: Box–Behnken Optimization and In Silico Mechanistic Insights for Dengue‑Associated Thrombocytopenia
Carica papaya L. leaf extract has long been recognized for its therapeutic potential in dengue-associated thrombocytopenia through enhancement of platelet production and inhibition of dengue viral proteases.
Simulations Plus to Host Virtual Investor Day Highlighting Strategy for the Next Era of Model-Informed Drug Development
Driving Growth with Integrated Software, Services, and AI-Enabled Ecosystem
Comprehensive PBPK Evaluation of Phenytoin and Indomethacin: Dose, Age, Pregnancy and Drug–Drug Interaction Insights
Understanding the pharmacokinetics (PK) of antiepileptic and anti-inflammatory drugs under different physiological conditions is essential for optimizing therapy.
Simulations Plus Announces First Quarter Fiscal Year 2026 Earnings and Conference Call Date
Conference call to be on Thursday, January 8, 2026, at 5 p.m. ET
Descriptor-First Approach for ADMET Prediction in the PolarisHub Antiviral Challenge
The prediction of absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties remains a central bottleneck in small-molecule discovery.
Vision, Mission and Values
To improve health through innovative solutions.
Mechanistic Modeling of Intramuscular Administration of a Long-acting Injectable Accounting for Tissue Response At the Depot Site
The tissue response to long-acting injectables (LAIs) suspension injection may impact the product in vivo performance.